Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Orlistat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNLIP known ✓ | P16233 | 1/20 | 1.00 |
| ▸ | DAGLA | Q9Y4D2 | 8/20 | 1.00 |
| ▸ | CNR1 | P21554 | 5/20 | 1.00 |
| ▸ | DAGLB | Q8NCG7 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABHD16A | O95870 | 1/20 | 1.00 |
| ▸ | LPL | P06858 | 1/20 | 1.00 |
| ▸ | LIPC | P11150 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | FASN | P49327 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 1.00 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 1.00 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 1.00 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129379 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL4129375 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL13210085 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL4132911 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL3270614 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL2473855 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL16408 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL12083554 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL22252870 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL10922890 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101317817-A | External slimming coating agent | ZHONGHUA YUAN (CN) | 2008-12-10 | — | — | CN | claimed |
| EP-4370519-A1 | 5,6,7,8-TETRAHYDRO-2,6- AND 2,7-NAPHTHYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES RESPONSIVE TO CITRATE TRANSPORTER MODULATION | Eternygen UK Ltd. (GB) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023159866-A1 | DRUG FOR INHIBITING DIETARY OBESITY AND POLYPEPTIDE USED THEREBY | 中国科学院动物研究所 | 2023-08-31 | — | — | WO | disclosed |
| EP-4198059-A1 | MODULATION OF CELLULAR STRESS | The University of Queensland (AU) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023285583-A1 | 5,6,7,8-TETRAHYDRO-2,6- AND 2,7-NAPHTHYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES RESPONSIVE TO CITRATE TRANSPORTER MODULATION | ETERNYGEN UK LTD. (GB) | 2023-01-19 | — | — | WO | disclosed |
| US-20210299118-A1 | Coordinated Metabolic Reprogramming in Response to Productive Viral Infections | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2021-09-30 | — | — | US | disclosed |
| US-11083725-B2 | Coordinated metabolic reprogramming in response to productive viral infections | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200353048-A1 | METHOD OF TREATING A METABOLIC DISORDER OF THE LIVER | UNIV QUEENSLAND (AU) | 2020-11-12 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10695406-B2 | Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent | THE UNIVERSITY OF QUEENSLAND (AU) | 2020-06-30 | — | — | US | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1682494-A4 | ARALKYL AMINES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1682494-A1 | ARALKYL AMINES AS CANNABINOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1663113-A2 | SUBSTITUTED SULFONAMIDES | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| CN-1768041-A | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO INC (US) | 2006-05-03 | — | — | CN | disclosed |
| WO-2005100382-A1 | VERTEBRATE PEPTIDE MODULATORS OF LIPID METABOLISM | BLM GROUP, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005044785-A1 | ARALKYL AMINES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005027837-A2 | SUBSTITUTED SULFONAMIDES | MERCK & CO., INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695406-B2 | Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent | XBP1, HSPA5, IAPP | PNLIP 19/4885DAGLA 1719/4885CNR1 1584/4885 |
| US-20200353048-A1 | METHOD OF TREATING A METABOLIC DISORDER OF THE LIVER | FABP1, OAT, GLS2 | PNLIP 55/4885DAGLA 1672/4885CNR1 2317/4885 |
| US-20210299118-A1 | Coordinated Metabolic Reprogramming in Response to Productive Viral Infections | MAVS, ATF4, PC | PNLIP 1101/4885DAGLA 4165/4885CNR1 3791/4885 |
| US-11083725-B2 | Coordinated metabolic reprogramming in response to productive viral infections | MAVS, ATF4, PC | PNLIP 1101/4885DAGLA 4165/4885CNR1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.